Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.24.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:        
Research and development $ 12,039 $ 10,945 $ 24,253 $ 18,649
General and administrative 3,155 3,447 6,855 5,961
Total operating expenses 15,194 14,392 31,108 24,610
Operating loss (15,194) (14,392) (31,108) (24,610)
Non-operating income (expense):        
Interest and other income, net 1,303 849 2,707 1,249
Loss from change in fair value of derivative liability (18) (13) (32) (26)
Total non-operating income, net 1,285 836 2,675 1,223
Net loss (13,909) (13,556) (28,433) (23,387)
Other comprehensive income:        
Net unrealized gain on available-for-sale marketable debt securities 236   303  
Comprehensive loss $ (13,673) $ (13,556) $ (28,130) $ (23,387)
Net loss per common share - basic (in dollars per share) $ (0.27) $ (0.26) $ (0.55) $ (0.46)
Net loss per common share - diluted (in dollars per share) $ (0.27) $ (0.26) $ (0.55) $ (0.46)
Weighted average number of common shares outstanding - basic (in shares) 51,408 51,410 51,409 50,969
Weighted average number of common shares outstanding - diluted (in shares) 51,408 51,410 51,409 50,969